Please login to the form below

Not currently logged in
Email:
Password:

CureVac appoints chief financial officer

Pierre Kemula joins the mRNA company’s management board

CureVac Pierre KemulaTübingen, Germany-based mRNA firm CureVac has appointed Pierre Kemula as its new chief financial officer.

Kemula will have responsibility for managing CureVac's financial and capital markets activities and joins the company's management board.

Previously, Kemula served as chief financial officer of Pixium Vision, a medical technology company specialising in the development of technologies for patients with outer retinal degeneration.

He also brings experience from Ipsen, where he was vice president of corporate finance, treasury and financial markets, and from consulting firms Roland Berger, Kea & Partners, Gemini Consulting and KPMG.

Ingmar Hoerr, co-founder and chief executive officer of CureVac, said: "Adding an executive with Pierre's financial and transactional expertise, as well as his global markets experience, is a key accomplishment for CureVac as the company prepares for multiple near-term corporate and clinical milestones that have the potential to significantly contribute to its leadership position in the field of mRNA."

14th October 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

What are you doing, Dave?
Artificial Intelligence (AI) is invading all areas of healthcare. Is it our saviour or our nemesis?...
Fake News is Bad for your Health
Ill informed patients make poor health decisions...
Secrets of Pharma Advertising
If the goal of branding is to be different, why do so many Pharma brand ads look the same?...

Infographics